Vanguard Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-4,526,920
| Closed | -$215M | – | 4332 |
|
|
2025
Q3 | $215M | Sell |
4,526,920
-2,708
| -0.1% | -$131K | ﹤0.01% | 1506 |
|
|
2025
Q2 | $242M | Buy |
4,529,628
+298,984
| +7% | +$13.6M | ﹤0.01% | 1424 |
|
|
2025
Q1 | $171M | Buy |
4,230,644
+526,233
| +14% | +$22.3M | ﹤0.01% | 1550 |
|
|
2024
Q4 | $103M | Buy |
3,704,411
+27,830
| +0.8% | +$843K | ﹤0.01% | 1859 |
|
|
2024
Q3 | $105M | Sell |
3,676,581
-28,509
| -0.8% | -$743K | ﹤0.01% | 1848 |
|
|
2024
Q2 | $86.9M | Buy |
3,705,090
+35,167
| +1% | +$752K | ﹤0.01% | 1900 |
|
|
2024
Q1 | $92.7M | Buy |
3,669,923
+584,875
| +19% | +$14M | ﹤0.01% | 1903 |
|
|
2023
Q4 | $72M | Buy |
3,085,048
+72,866
| +2% | +$1.44M | ﹤0.01% | 2026 |
|
|
2023
Q3 | $152M | Buy |
3,012,182
+326,308
| +12% | +$15.2M | ﹤0.01% | 1573 |
|
|
2023
Q2 | $125M | Buy |
2,685,874
+546,981
| +26% | +$25.1M | ﹤0.01% | 1730 |
|
|
2023
Q1 | $81.8M | Buy |
2,138,893
+22,322
| +1% | +$995K | ﹤0.01% | 1917 |
|
|
2022
Q4 | $116M | Buy |
2,116,571
+375,978
| +22% | +$16.1M | ﹤0.01% | 1727 |
|
|
2022
Q3 | $59.3M | Buy |
1,740,593
+429,579
| +33% | +$6.57M | ﹤0.01% | 2100 |
|
|
2022
Q2 | $12.4M | Buy |
1,311,014
+84,103
| +7% | +$877K | ﹤0.01% | 2872 |
|
|
2022
Q1 | $17.4M | Buy |
1,226,911
+56,492
| +5% | +$989K | ﹤0.01% | 2848 |
|
|
2021
Q4 | $24.8M | Buy |
1,170,419
+89,834
| +8% | +$1.99M | ﹤0.01% | 2726 |
|
|
2021
Q3 | $24.2M | Buy |
1,080,585
+20,949
| +2% | +$474K | ﹤0.01% | 2750 |
|
|
2021
Q2 | $26.3M | Buy |
1,059,636
+73,916
| +7% | +$2.08M | ﹤0.01% | 2705 |
|
|
2021
Q1 | $28.6M | Buy |
985,720
+102,157
| +12% | +$3.09M | ﹤0.01% | 2605 |
|
|
2020
Q4 | $22.8M | Buy |
883,563
+29,790
| +3% | +$829K | ﹤0.01% | 2571 |
|
|
2020
Q3 | $26.3M | Buy |
853,773
+313,697
| +58% | +$11M | ﹤0.01% | 2323 |
|
|
2020
Q2 | $13.5M | Buy |
540,076
+233,357
| +76% | +$5.33M | ﹤0.01% | 2622 |
|
|
2020
Q1 | $6.5M | Buy |
306,719
+22,123
| +8% | +$474K | ﹤0.01% | 2831 |
|
|
2019
Q4 | $6.32M | Buy |
284,596
+100,071
| +54% | +$2.07M | ﹤0.01% | 3086 |
|
|
2019
Q3 | $4.2M | Buy |
184,525
+154,525
| +515% | +$3.6M | ﹤0.01% | 3200 |
|
|
2019
Q2 | $574K | Buy |
+30,000
| New | +$569K | ﹤0.01% | 3802 |
|
Other funds holding AKRO
Vanguard Group's AKRO Position: Q4 2025 in Review
Vanguard Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 4,526,920 shares — an estimated $215M sold.
Vanguard Group first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $242M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Vanguard Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Vanguard Group sold 4,526,920 Akero Therapeutics shares in Q4 2025, an estimated $215M.
- Vanguard Group first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- Vanguard Group's Akero Therapeutics position peaked at $242M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.